The stock price of Beta Bionics Inc (NASDAQ: BBNX) has jumped by 12.24 compared to previous close of 15.36. Despite this, the company has seen a gain of 11.15% in its stock price over the last five trading days. seekingalpha.com reported 2025-05-10 that Beta Bionics, Inc. (NASDAQ:BBNX ) Q1 2025 Results Conference Call May 6, 2025 4:30 PM ET Company Participants Blake Beber – Head, IR Sean Saint – President and Chief Executive Officer Stephen Feider – Chief Financial Officer Conference Call Participants Matthew O’Brien – Piper Sandler Mike Kratky – Leerink Partners Matthew Blackman – Stifel Travis Steed – Bank of America Jeffrey Cohen – Ladenburg Thalmann Brooks O’Neil – Lake Street Capital Markets Kelly Close – Close Concerns Operator Good afternoon, and welcome to the Beta Bionics First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Is It Worth Investing in Beta Bionics Inc (NASDAQ: BBNX) Right Now?
Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for BBNX is 33.22M, and currently, short sellers hold a 10.70% ratio of that float. The average trading volume of BBNX on June 02, 2025 was 527.16K shares.
BBNX’s Market Performance
BBNX’s stock has seen a 11.15% increase for the week, with a 56.02% rise in the past month and a -17.79% fall in the past quarter. The volatility ratio for the week is 6.28%, and the volatility levels for the past 30 days are at 7.23% for Beta Bionics Inc The simple moving average for the past 20 days is 21.04% for BBNX’s stock, with a 10.94% simple moving average for the past 200 days.
Analysts’ Opinion of BBNX
Many brokerage firms have already submitted their reports for BBNX stocks, with Wolfe Research repeating the rating for BBNX by listing it as a “Outperform.” The predicted price for BBNX in the upcoming period, according to Wolfe Research is $20 based on the research report published on May 30, 2025 of the current year 2025.
Goldman, on the other hand, stated in their research note that they expect to see BBNX reach a price target of $16. The rating they have provided for BBNX stocks is “Neutral” according to the report published on May 30th, 2025.
Stifel gave a rating of “Buy” to BBNX, setting the target price at $25 in the report published on February 24th of the current year.
BBNX Trading at 36.19% from the 50-Day Moving Average
After a stumble in the market that brought BBNX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.63% of loss for the given period.
Volatility was left at 7.23%, however, over the last 30 days, the volatility rate increased by 6.28%, as shares surge +54.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.18% upper at present.
During the last 5 trading sessions, BBNX rose by +11.15%, in comparison to the 20-day moving average, which settled at $14.24. In addition, Beta Bionics Inc saw -27.04% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BBNX starting from Mensinger Mike, who purchase 33,350 shares at the price of $17.00 back on Jan 31 ’25. After this action, Mensinger Mike now owns 59,019 shares of Beta Bionics Inc, valued at $566,950 using the latest closing price.
Mensinger Mike, the Chief Product Officer of Beta Bionics Inc, sale 13 shares at $17.00 during a trade that took place back on Jan 31 ’25, which means that Mensinger Mike is holding 25,669 shares at $221 based on the most recent closing price.
Stock Fundamentals for BBNX
Current profitability levels for the company are sitting at:
- -0.77 for the present operating margin
- 0.54 for the gross margin
The net margin for Beta Bionics Inc stands at -1.02. The total capital return value is set at -0.16.
Based on Beta Bionics Inc (BBNX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -6.65.
Currently, EBITDA for the company is -44.1 million with net debt to EBITDA at 0.7. When we switch over and look at the enterprise to sales, we see a ratio of 10.51. The receivables turnover for the company is 6.15for trailing twelve months and the total asset turnover is 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.88.
Conclusion
To put it simply, Beta Bionics Inc (BBNX) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
